Rivaroxaban for the prevention of atherothrombotic events in advanced CKD: are we off TRACK?

Bjorn K I Meijers, Thomas Mavrakanas; Rivaroxaban for the prevention of atherothrombotic events in advanced CKD: are we off TRACK?, Clinical Kidney Journal

Authors

Institutions

Publication Details

Journal
Clinical Kidney Journal
Published
2026-06-27
DOI
https://doi.org/10.1093/ckj/sfag220
Primary Topic
Atrial Fibrillation Management and Outcomes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Rivaroxaban for the prevention of atherothrombotic events in advanced CKD: are we off TRACK?

Björn Meijers, Thomas Mavrakanas
Clinical Kidney Journal
Atrial Fibrillation Management and Outcomes
article

Rivaroxaban for the prevention of atherothrombotic events in advanced CKD: are we off TRACK?

Björn Meijers, Thomas Mavrakanas
article en

Abstract

Bjorn K I Meijers, Thomas Mavrakanas; Rivaroxaban for the prevention of atherothrombotic events in advanced CKD: are we off TRACK?, Clinical Kidney Journal

Clinical Kidney Journal
McGill University Health Centre (CA), McGill University (CA), KU Leuven (BE)
Zero hunger
Openalex Percentile: Top 8%
Atrial Fibrillation Management and Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.